LianBio soars on successful heart disease drug trial in China

LianBio

26/04/2023 16:00

** Shares of biotech company LianBio  LIAN.O  up 10.3% at
$2.13
    ** Heart disease drug Mavacamten meets key goal in
late-stage trial in China to treat hypertrophic cardiomyopathy,
a condition in which the heart muscle becomes abnormally thick
    ** Lianbio licensed rights for the development and
commercialization of Mavacamten in China in 2020 from MyoKardia,
now a unit of Bristol-Myers Squibb  BMY.N  
    ** Earlier this month, LIAN said its marketing application,
or NDA, was accepted by Chinese regulators with priority review
    ** "With positive pivotal data now in hand and the NDA on
file, we are optimistic about bringing Mavacamten to market in
China next year," says LianBio CEO Yizhe Wang
    ** Lian up 23.8% YTD

 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((nandhini.srinivasan@thomsonreuters.com))